Evidence map›Paper›PMID 36619819›Full record

ArticleToxicon: X2023

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues.

Julien Potet, Saschveen Singh, Koert Ritmeijer, Kasaye Sisay, Gabriel Alcoba, Fabienne Jouberton, Yannick Wilson Henko Kinding, Alexandra Kruse, Aboubacar Bengaly, Malwal Sabino and 2 more

Open access · goldAbstract read
In one paragraph

Article in Toxicon: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Western Bush Viper (Atheris chlorechis) Envenomation: A Case Report.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 6 countries.

Julien PotetMédecins Sans Frontières, Paris, France.
Saschveen SinghMédecins Sans Frontières, Paris, France.
Koert RitmeijerMédecins Sans Frontières, Amsterdam, Netherlands.
Kasaye SisayMédecins Sans Frontières, Abdurafi, Ethiopia.
Gabriel AlcobaMédecins Sans Frontières, Geneva, Switzerland.
Fabienne JoubertonMédecins Sans Frontières, Geneva, Switzerland.
Yannick Wilson Henko KindingMédecins Sans Frontières, Bangassou, Central African Republic.
Alexandra KruseMédecins Sans Frontières, Brussels, Belgium.
Aboubacar BengalyMédecins Sans Frontières, Paoua, Central African Republic.
Malwal SabinoMédecins Sans Frontières, Aweil, Sudan.
Narcisse Patrice KomasInstitut Pasteur de Bangui, Bangui, Central African Republic.
Matthew ColdironEpicentre, Paris, France.
Médecins Sans Frontières · FRMédecins Sans Frontières · CHInstitut Pasteur de Bangui · CFMédecins Sans Frontières · BEMédecins Sans Frontières · UGMédecins Sans Frontières · NLUniversity of Bangui · CF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each year. We describe our activities against snakebite in three African countries: Central African Republic, South Sudan and Ethiopia, in which different models of care have been developed. A standard protocol using two different antivenoms depending on the patient's syndrome has been introduced, and a simple blood coagulation test is performed to detect venom-induced coagulopathy. Other services, including surgery for necrotizing wounds, are offered in the facilities where MSF admits a large number of snakebite patients. All services, including provision of antivenom, are offered free-of-charge in MSF-supported facilities. Community-based activities focusing on preventive measures and prompt transport to hospital have been developed in a few MSF projects. The provision of quality care and treatment, including effective antivenoms, without out-of-pocket payments by the patients, probably explains why MSF has admitted an increasing number of snakebite victims over the last years. This model requires significant resources and monitoring, including regular training of healthcare workers on treatment protocols and a considerable budget for antivenom procurement.

Indexed as

AntivenomsCentral African RepublicEthiopiaSnakebite envenomingSouth Sudan

Identifiers

PMID36619819
PMCPMC9813776
OpenAlexW4313214841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.